期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Role of targeting ferroptosis as a component of combination therapy in combating drug resistance in colorectal cancer 被引量:1
1
作者 Xiao-Ting Xie qiang-hu pang Lian-Xiang Luo 《World Journal of Clinical Oncology》 2024年第3期375-377,共3页
Colorectal cancer(CRC)is a form of cancer that is often resistant to chemotherapy,targeted therapy,radiotherapy,and immunotherapy due to its genomic instability and inflammatory tumor microenvironment.Ferroptosis,a ty... Colorectal cancer(CRC)is a form of cancer that is often resistant to chemotherapy,targeted therapy,radiotherapy,and immunotherapy due to its genomic instability and inflammatory tumor microenvironment.Ferroptosis,a type of non-apoptotic cell death,is characterized by the accumulation of iron and the oxidation of lipids.Studies have revealed that the levels of reactive oxygen species and glutathione in CRC cells are significantly lower than those in healthy colon cells.Erastin has emerged as a promising candidate for CRC treatment by diminishing stemness and chemoresistance.Moreover,the gut,responsible for regulating iron absorption and release,could influence CRC susceptibility through iron metabolism modulation.Investigation into ferroptosis offers new insights into CRC pathogenesis and clinical management,potentially revolutionizing treatment approaches for therapy-resistant cancers. 展开更多
关键词 Colorectal cancer Ferroptosis IMMUNOTHERAPY Drug resistance CHEMOTHERAPY Nanodrug delivery systems
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部